Lancet
-
Randomized Controlled Trial Multicenter Study
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.
Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. ⋯ British Heart Foundation, the UK Marfan Trust, the UK Marfan Association.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy characterised by multiple types of frequent, disabling seizures. Fenfluramine has been reported to have antiseizure activity in observational studies of photosensitive epilepsy and Dravet syndrome. The aim of the present study was to assess the efficacy and safety of fenfluramine in patients with Dravet syndrome. ⋯ Zogenix.